Letairis Related Published Studies
Well-designed clinical trials related to Letairis (Ambrisentan)
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. [2010.02]
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial
hypertension. [2010]
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. [2009.11.17]
Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. [2008.12]
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. [2008.06.10]
Ambrisentan therapy for pulmonary arterial hypertension. [2005.08.02]
Well-designed clinical trials possibly related to Letairis (Ambrisentan)
Race and sex differences in response to endothelin receptor antagonists for
pulmonary arterial hypertension. [2012]
[Treatment of pulmonary fibrosis : New substances and new interventions.] [2011.11.19]
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. [2009]
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.] [2005.06]
Other research related to Letairis (Ambrisentan)
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary
hypertension. [2012]
Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. [2011.09]
Ambrisentan. [2011.08.01]
Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. [2011.07.15]
Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. [2011.05.01]
Pharmacokinetic evaluation of ambrisentan. [2011.03]
Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. [2011.01]
Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. [2011]
Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. [2010.10]
Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. [2010]
Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. [2010]
Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. [2009.08]
Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. [2009.06]
The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. [2009.05]
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. [2009.01]
Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer. [2009]
Ambrisentan and its role in the management of pulmonary arterial hypertension. [2008.12]
Role of ambrisentan in the management of pulmonary hypertension. [2008.11]
Ambrisentan for the management of pulmonary arterial hypertension. [2008.05]
Raltegravir. [2008]
A review of pulmonary arterial hypertension: role of ambrisentan. [2007]
Ambrisentan, a non-peptide endothelin receptor antagonist. [2006.03]
Other possibly related research studies
Endothelin receptor antagonism : role in the treatment of pulmonary arterial hypertension related to scleroderma. [2008]
[Systemic sclerosis] [2008.05]
Management of pulmonary arterial hypertension associated with congenital heart disease. [2007]
[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008] [2008.04]
Endothelin receptor antagonists in pulmonary arterial hypertension. [2008.02]
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? [2008.03]
Expert opinion on available options treating pulmonary arterial hypertension. [2007.10]
Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. [2007.10]
Gateways to clinical trials. [2007.04]
EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils. [2007.07.09]
Gateways to clinical trials. [2007.03]
Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. [2007.03]
Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition? [2006.12]
[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists] [2006.12.08]
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. [2006.09]
Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. [2005.12]
Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. [2006.06]
Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. [2006.06]
Gateways to clinical trials. [2006.01]
Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelin A receptor blockade after orthotopic liver transplantation in pigs. [2006.01]
Gateways to clinical trials. [2005.10]
Drug treatment of pulmonary arterial hypertension: current and future agents. [2005]
[Treatment algorithm for pulmonary arterial hypertension.] [2005.06]
Gateways to clinical trials. [2004.10]
Endothelin receptor antagonists in pulmonary arterial hypertension. [2004.06.16]
Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis. [2004.06]
Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function. [2002.08]
[Specific drugs for the treatment of pulmonary arterial hypertension - current status] [2008.10]
Pulmonary arterial hypertension: on the way to a manageable disease. [2008.09]
Gateways to clinical trials. [2008.03]
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. [2008]
[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment] [2008.08]
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? [2008.08]
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. [2008]
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. [2009.06]
Pulmonary arterial hypertension in children: a medical update. [2009.01]
Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis. [2010.04.28]
Pharmacotherapeutic management of pulmonary arterial hypertension. [2010.05]
[Endothelin receptor antagonists - their role in pulmonary medicine] [2009.12]
Therapeutic methods used in patients with Eisenmenger syndrome. [2009]
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. [2009.09.21]
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. [2009.12]
Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. [2009]
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. [2009.06]
Endothelin receptor antagonists - their role in pulmonary medicine. [2011.10]
[Treatment of idiopathic pulmonary arterial hypertension]. [2011.07.01]
Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. [2011.06]
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. [2011.07]
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. [2011.03]
Endothelin receptor antagonists as disease modifiers in systemic sclerosis. [2011.02]
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. [2010.12.01]
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. [2011.03]
Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis. [2010.05]
Pulmonary arterial hypertension in connective tissue diseases. [2010.03]
Non-congenital heart disease associated pediatric pulmonary arterial hypertension. [2009.12.01]
|
